Radioactive drug development is a multi-disciplinary task, therefore, in a concerted effort, dedicated scientists and experts from different fields of specialisation have contributed to this book. It is presented in two sections. Section 1 contains basic principles and methods used for analysis, information on the chemistry of technetium and on radiopharmaceuticals labelled with technetium-99m, the characteristics of the 99 Mo/99mTc-generator, of 'kits' and formulations for in-vitro labelling, and special safety aspects for in-vivo labelling of blood cells. Section 2 contains monographs of 99mTc-radiopharmaceuticals used in nuclear medicine. Each monograph includes information on the chemistry, formulation, commercial products and trade names, factors affecting in-vivo performance, clinical information on pharmacokinetics, as well as details concerning the clinical application and the radiation dose to patients.

I

Drug Safety
Technetium in Medicine
Stannous Chloride in the Preparation of 99mTc Pharmaceuticals
Quality Assurance of Radiopharmaceuticals
Performance and Quality Control of the 99Mo/99mTc Generator
Preparation of Technetium 99mTc Pharmaceuticals
Lyophilization Technique for Preparing Radiopharmaceutical Kits
Cellular Labeling with 99mTc Chelates: Relevance of In Vitro and In Vivo Viability Testing
Quality Control Methods of 99mTc Pharmaceuticals
Other Technetium Isotopes: 94mTc as a Potential Substitute in Positron Emission Tomography Investigations
The Rules Governing Medicinal Products for Human Use in the European Union
II
Monographs of 99mTc Pharmaceuticals.